We have two compounds in clinical development, a Factor Xa inhibitor and an ADP receptor antagonist, each with the potential to improve and simplify patient care in multi-billion dollar markets where there is a significant unmet need. Portola also has a robust preclinical pipeline leveraging its in-house research and development expertise in the cardiovascular field.